The window Moscow is working to keep shut

Everything else in this issue looks at the reconsolidation window from the clinic's side: how to prise it open, how to weaken a fear memory once it is labile, why the drugs keep failing to do it in humans. This paper, from Konstantin Anokhin's group at the Institute for Advanced Brain Studies at Lomonosov Moscow State University, comes at the same window from the opposite direction. It asks how to hold the window shut – and answers with a drug that is already in millions of prescriptions.

The same lever, pulled the other way

The logic runs through Alzheimer's disease rather than trauma. Tiunova, Diffine and Anokhin start from a hypothesis about self-degradation: if reconsolidation is what keeps an old memory alive across each retrieval, then in a brain where that machinery is compromised, the act of remembering is itself the thing that erodes the memory. Recall becomes lossy. On that reading, the way to slow the erosion is not to strengthen the memory but to stop it from destabilising in the first place.

The test is a passive avoidance task in two-day-old chicks – peck a bitter bead once, avoid an identical dry bead thereafter. The design's value is its timing. Training, reminder at 2 hours, test at 4 or 24 hours, peptide at 45 minutes and antagonist at 30 minutes before the reminder. That resolution is what makes the result legible: beta-amyloid at 4 micrograms wrecked retention when it arrived just before the reminder (chi-square = 8.96 vs control, p less than 0.001), and did nothing at all when the same dose arrived at the same post-training moment with no reminder given. The reminder is the whole effect. What amyloid damages is not the memory but the reopening of it.

Then the reversal. MK-801, a non-competitive NMDA antagonist, blocks that reopening – and blocking it protects the memory from amyloid (p less than 0.01). The authors then swapped in memantine at 0.73 mg/kg, which is the same class of drug and is prescribed to dementia patients every day. Same rescue, at 4 hours (chi-square = 5.12, p less than 0.05) and 24 hours (chi-square = 13.58, p less than 0.001), and without MK-801's own amnestic cost. The proposal in the discussion is that part of memantine's clinical benefit may be that it stops old memories from labilising when patients reach for them.

What this community is actually contributing

Note what has to exist for this result to be possible. A tradition – the chick passive avoidance paradigm has been worked in this lineage for decades, long enough that its consolidation and reconsolidation pharmacology is mapped in fine detail. An animal facility running 906 birds through a single set of experiments. And a group that treats the destabilisation step as an object of study in its own right, rather than as a means to a therapeutic end. That is the contribution: not a treatment, but the mechanism sitting underneath the treatments we already deliver.

This matters to our field for an uncomfortable reason. Exposure and EMDR are, in their mechanistic tellings, bets that retrieval makes a memory editable. Nobody in a consulting room measures whether the window opened. Anokhin's group can tell you that in chicks the window is NMDA-dependent, that in chicks it is pharmacologically separable from consolidation, and that in chicks it can be closed on purpose. Point 2 above should also give the field pause: in this model the standard amnestic agents produce deficits that recover by 24 hours – the memory comes back – whereas amyloid's did not. If "reconsolidation blockade" in animals is often a temporary retrieval failure that spontaneously reverses, the clinical translation problem starts earlier than the trial design.

And there is a question here for practice that I want to state as a question, not a finding. If a patient on memantine has a pharmacologically stiffer memory, what happens to therapy that depends on memory being editable? In chicks, that is what memantine does. In a dementia clinic, nobody has looked.